North Estonia Medical Centre

From Beacon

The North Estonia Medical Centre is one of the top healthcare providers in the country. Its statutes states that their goal is "to provide high-quality, specialized medical care and ambulance services, to be the learning base of training that precedes and follows the acquiring of health care professionals’ qualifications and does healthcare-related study and research work."

Trials

Study of AGEN2034 in Advanced Tumors and Cervical Cancer

Summary: This is a 2-part trial: a Phase 1, open-label, dose-escalation study in subjects with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in subjects with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum-based treatment regimen.

Sponsor, manager, or home institution: Agenus Inc.

Intervention/Treatment: Drug: AGEN2034

Number of patients: 211 participants

Beginning Date: April 7, 2017

Last Update: November 3, 2022

Recruitment Status: Completed.

Cancer areas of interest: Advanced Cancer and Cervical Cancer

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

Summary: This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival.

Sponsor, manager, or home institution: Merck Sharp & Dohme LLC

Intervention/Treatment: Drug: Pembrolizumab; Radiation: Conventional Radiotherapy (Bladder only); Radiation: Conventional Radiotherapy (Bladder and pelvic nodes); Radiation: Hypofractionated Radiotherapy (Bladder only); Drug: Cisplatin; Drug: Fluorouracil (5-FU); Drug: Mitomycin C (MMC); Drug: Gemcitabine; Drug: Placebo to Pembrolizumab

Number of patients: 636 participants

Beginning Date: January 27, 2020

Last Update: October 21, 2022

Recruitment Status: Recruiting.

Cancer areas of interest: Urinary Bladder Neoplasms

Experts

Learning Resources

Patient School

Content Type: E-courses and lectures.

Target Audience: For everyone.

Availability in English: No.

"Chest Cabinet"

Content Type: Local support for concerns on breast cancer.

Target Audience: Women of all ages.

Learning Resources for Relatives and Caretakers

Content Type: Guides and counseling appointment information.

Target Audience: Patients, Relatives and Caretakers.

Other Learning Materials

Cancer-related Patient Associations

Patient Advisory Council

Primary Purpose: To ensure the interests of the patient are being taken into account when making decisions and designing services, and that the patient has an active role in the treatment process.

Members: Estonian Rheumatism Association; Avitus NGO; Estonian Inflammatory Bowel Disease Society NGO; Estonian Celiac Society; Estonian Psoriasis Association; Estonian Hemophilia Society; Estonian Chamber of Disabled People; Tallinn Chamber of Disabled People; Saaremaa Cancer Society; Läänemaa Cancer Association; Estonian Stroke Patients Society.